364
Views
68
CrossRef citations to date
0
Altmetric
Original Articles

Investigation of “Bath Salts” Use Patterns Within an Online Sample of Users in the United States

, Ph.D. & , Ph.D.

REFERENCES

  • Aarde, S.M.; Huang, P.K.; Creehan, K.M.; Dickerson, T.J. & Taffe, M.A. 2013. The novel recreational drug 3.4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats. Neuropharmacology 71: 130–40.
  • American Psychiatric Association. 2013. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
  • Anthony, J.C.; Warner, L.A. & Kessler, R.C. 1994. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology 2 (3): 244–68.
  • Barratt, M.J. 2012. Silk Road: eBay for drugs. Addiction 107 (3): 683.
  • Baumann, M.H.; Partilla, J.S. & Lehner, K.R. 2013a. Psychoactive “bath salts”: Not so soothing. European Journal of Pharmacology 698 (1–3): 1–5.
  • Baumann, M.H.; Partilla, J.S.; Lehner, K.R.; Thorndike, E.B.; Hoffman, A.F.; Holy, M.; Rothma, R.B.; Goldberg, S.R.; Lupica, C.R.; Sitte, H.H.; Brandt, S.D.; Tella, S.R.; Cozzi, N.V. & Schindler, C.W. 2013b. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive “bath salts” products. Neuropsychopharmacology 38 (4): 552–62.
  • Booth, R.E.; Watters, J.K. & Chitwood, D.D. 1993. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. American Journal of Public Health 83 (8): 1144–8.
  • Bronstein, A.C.; Spyker, D.A.; Cantilena Jr., L.R.; Green, J.L.; Rumack & Dart, R.C. 2011. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report. Clinical Toxicology 49 (10): 910–41.
  • Brown, A.H.; Domier, C.P. & Rawson, R.A. 2005. Stimulants, sex, and gender. Sexual Addiction & Compulsivity 12 (2–3): 169–80.
  • Bux, D.A.; Lamb, R.J. & Iguchi, M.Y. 1995. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug and Alcohol Dependence 37 (1): 29–35.
  • Cameron, K.N.; Kolanos, R.; Solis Jr., E.; Glennon, R.A. & De Felice, L.J. 2013. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. British Journal of Pharmacology 168 (7): 1750–7.
  • Carhart-Harris, R.L.; King, L.A. & Nutt, D.J. 2011. A web-based survey on mephedrone. Drug and Alcohol Dependence 118 (1): 19–22.
  • De Paoli, G.; Maskell, P.D. & Pounder, D.J. 2011. Naphyrone: Analytical profile of the new “legal high” substitute for mephedrone. Journal of Forensic and Legal Medicine 18 (2): 93.
  • Eshleman, A.J.; Wolfrum, K.M.; Hatfield, M.G.; Johnson, R.A.; Murphy, K.V. & Janowsky, A. 2013. Substituted methcathinones differ in transporter and receptor interactions. Biochemical Pharmacology 85 (12): 1803–15.
  • Fantegrossi, W.E.; Gannon, B.M.; Zimmerman, S.M. & Rice, K.C. 2013. In vivo effects of abused “bath salt” constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38 (4): 563–73.
  • Forrester, M.B. 2012. Synthetic cathinone exposures reported to Texas poison centers. The American Journal of Drug and Alcohol Abuse 38 (6): 609–15.
  • Gatch, M.B.; Taylor, C.M. & Forster, M.J. 2013. Locomotor stimulant and discriminative stimulus effects of “bath salt” cathinones. Behavioral Pharmacology 24 (5–6): 437–47.
  • Gonzales, R.; Mooney, L. & Rawson, R.A. 2010. The methamphetamine problem in the United States. Annual Review of Public Health 31: 385–98.
  • Hart, C.L.; Gunderson, E.W.; Perez, A.; Kirkpatrick, M.G.; Thurmond, A.; Comer, S.D. & Foltin, R.W. 2008. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 33 (8): 1847–55.
  • Hatsukami, D.K. & Fischman, M.W. 1996. Crack cocaine and cocaine hydrochloride: Are the differences myth or reality? JAMA: The Journal of the American Medical Association 276 (19): 1580–8.
  • Hoffman, J.A.; Klein, H.; Eber, M. & Crosby, H. 2000. Frequency and intensity of crack use as predictors of women’s involvement in HIV-related sexual risk behaviors. Drug and Alcohol Dependence 58 (3): 227–36.
  • Hudziak, J.J.; Helzer, J.E.; Wetzel, M.W.; Kessel, K.B.; McGee, B.; Janca, A. & Przybeck, T. 1993. The use of the DSM-III-R checklist for initial diagnostic assessments. Comprehensive Psychiatry 34 (6): 375–83.
  • Hursh, S.R. & Silberberg, A. 2008. Economic demand and essential value. Psychological Review 115 (1): 186–98.
  • Johnston, L.D.; O’Malley, P.M.; Bachman, J.G. & Schulenberg, J.E. 2013. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2012. Ann Arbor, MI: University of Michigan Institute for Social Research.
  • Johnston, L.D.; O’Malley, P.M.; Miech, R.A.; Bachman, J.G. & Schulenberg, J.E. 2014. Monitoring the Future National Survey Results on Drug Use: 1975-2013: Overview, Key Findings on Adolescent Drug Use. Ann Arbor, MI: University of Michigan Institute for Social Research.
  • Kelly, B.C.; Wells, B.E.; Pawson, M.; Leclair, A.; Parsons, J.T. & Golub S.A. 2013. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug and Alcohol Review 32 (6): 588–93.
  • Khey, D.N.; Stogner, J. & Miller, B.L. 2014. Emerging Trends in Drug Use and Distribution. Cham, Switzerland: Springer International Publishing.
  • López-Arnau, R.; Martínez-Clemente, J.; Pubill, D.; Escubedo, E. & Camarasa, J. 2012. Comparative neuropharmacology of three psychostimulant cathinone derivatives: Butylone, mephedrone and methylone. British Journal of Pharmacology 167 (2): 407–20.
  • Martinez, M. 2012. “Tests in cannibalism case: Zombie-like attacker used pot, not ‘bath salts’.” Available at: http://www.cnn.com/2012/06/27/us/florida-cannibal-attack. Accessed August 27, 2013.
  • Marusich, J.A.; Grant, K.R.; Blough, B.E. & Wiley, J.L. 2012. Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology 33 (5): 1305–13.
  • Miotto, K.; Striebel, J.; Cho, A.K. & Wang, C. 2013. Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports. Drug and Alcohol Dependence 132 (1–2): 1–12.
  • Motbey, C.P.; Clemens, K.J.; Apetz, N.; Winstock, A.R.; Ramsey, J.; Li, K.M.; Wyatt, N.; Callaghan, P.D.; Bowen, M.T.; Cornish, J.L. & McGregor, I.S. 2013. High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine. Journal of Psychopharmacology 27 (9): 823–36.
  • Murphy, C.M.; Dulaney, A.R.; Beuhler, M.C. & Kacinko, S. 2013. “Bath salts” and “plant food” products: The experience of one regional US poison center. Journal of Medical Toxicology 9 (1): 42–8.
  • O’Brien, C.P. 2011. Drug addiction. In: L.L. Brunton, B.A. Chabner & B.C. Knollman (Eds.) Goodman & Gilman’s Pharmacologic Basis of Therapeutics, 12th ed. New York: McGraw-Hill.
  • Penders, T.M.; Gestring, R.E. & Vilensky, D.A. 2012. Excited delirium following use of synthetic cathinones (bath salts). General Hospital Psychiatry 34 (6): 647–50.
  • Prosser, J.M. & Nelson, L.S. 2012. The toxicology of bath salts: A review of synthetic cathinones. Journal of Medical Toxicology 8 (1): 33–42.
  • Rosenbaum, C.D.; Carreiro, S.P. & Babu, K.M. 2012. Here today, gone tomorrow … and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. Journal of Medical Toxicology 8 (1): 15–32.
  • Ross, E.A.; Reisfield, G.M.; Watson, M.C.; Chronister, C.W. & Goldberger, B.A. 2012. Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. The American Journal of Medicine 125 (9): 854–8.
  • Shanks, K.G.; Dahn, T.; Behonick, G. & Terrell, A. 2012. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. Journal of Analytical Toxicology 36 (6): 360–71.
  • Simmler, L.D.; Buser, T.A.; Donzelli, M.; Schramm, Y.; Dieu, L.H.; Huwyler, J.; Chaboz, S.; Hoener, M.C. & Liechti, M.E. 2013. Pharmacological characterization of designer cathinones in vitro. British Journal of Pharmacology 168 (2): 458–70.
  • Spiller, H.A.; Ryan, M.L.; Weston, R.G. & Jansen, J. 2011. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clinical Toxicology 49 (6): 499–505.
  • Stogner, J.M. & Miller, B.L. 2013. Investigating the “bath salt” panic: The rarity of synthetic cathinone use among students in the United States. Drug and Alcohol Review 32 (5): 545–9.
  • Thornton, S.L.; Gerona, R.R. & Tomaszewski, C.A., 2012. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. Journal of Medical Toxicology 8 (3): 310–3.
  • Vandrey, R.; Johnson, M.W.; Johnson, P.S. & Khalil, M.A 2013. Novel drugs of abuse: A snapshot of an evolving marketplace. Adolescent Psychiatry 3 (2): 123–34.
  • Volkow, N.D.; Wang, G.J.; Fischman, M.W.; Foltin, R.; Fowler, J.S.; Franceschi, D.; Franceschi, M.; Logan, J;, Gatley, S.J.; Wong, C.; Ding, Y.S.; Hitzemann, R. & Pappas, N. 2000. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sciences 67 (12): 1507–15.
  • Warrick, B.J.; Hill, M.; Hekman, K.; Christensen, R;, Goetz, R.; Casavant, M.J.; Wahl, M.; Mowry, J.B.; Spiller, H.; Anderson, D.; Aleguas, A.; Gummin, D.; Thomas, R.; Nezlek, C. & Smolinske, S. 2013. A 9-state analysis of designer stimulant, “bath salt,” hospital visits reported to poison control centers. Annals of Emergency Medicine 62 (3): 244–51.
  • Watterson, L.R.; Hood, L.; Sewalia, K.; Tomek, S.E.; Yahn, S.; Johnson, C.T.; Wegner, S.; Blough, B.E.; Marusich, J.A. & Olive, M.F. 2012a. The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in “bath salts.” Journal of Addiction Research & Therapy Suppl 9: 002.
  • Watterson, L.R.; Kufahl, P.R.; Nemirovsky, N.E.; Sewalia, K.; Grabenauer, M.; Thomas, B.F.; Marusich, J.A.; Wegner, S. & Olive, M.F. 2012b. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MPDV). Addiction Biology 19 (2): 165–74.
  • Winstock, A.R.; Mitcheson, L.R.; Deluca, P.; Davey, Z.; Corazza, O. & Schifano, F. 2011a. Mephedrone, new kid for the chop? Addiction 106 (1): 154–61.
  • Winstock, A.; Mitcheson, L.; Ramsey, J.; Davies, S.; Puchnarewicz, M. & Marsden, J. 2011b. Mephedrone: Use, subjective effects and health risks. Addiction 106 (11): 1991–6.
  • Wood, D.M. & Dargan, P.I. 2012. Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 39 (2): 227–33.
  • Wood, K.E. 2013. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. The Journal of Pediatrics 163 (1): 213–6.
  • Yin, S. & Ho, M. 2012. Monitoring a toxicological outbreak using Internet search query data. Clinical Toxicology 50 (9): 818–22.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.